Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study

By Gauthier Serge  

Current Medical Research and Opinion, Vol. 29, Iss. 8, 2013-08 ,pp. : 989-1000

Informa Healthcare

Access to resources Recommend Favorite

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

By Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1375-1383

Informa Healthcare

Access to resources Recommend Favorite

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

By Farlow Martin R.   Alva Gus   Meng Xiangyi   Olin Jason T.  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 263-269

Informa Healthcare

Access to resources Recommend Favorite

A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study

By Gauthier Serge   Juby Angela   Morelli Lidia   Rehel Bonita   Schecter Robyn    

Current Medical Research and Opinion, Vol. 22, Iss. 11, 2006-11 ,pp. : 2251-2265

Informa Healthcare

Access to resources Recommend Favorite

Measuring Life Space in Older Adults with Mild-to-Moderate Alzheimer's Disease Using Mobile Phone GPS

By  

Gerontology, Vol. 60, Iss. 2, 2013-12 ,pp. : 154-162

Karger

Access to resources Recommend Favorite